Attention Deficit Hyperactivity Disorder (ADHD) is a neuropsychiatric medical problem whose main clinical manifestations are inattention, hyperactivity, and impulsivity. Many years ago, it was recognized in children, and it was popularly believed for so many years that its occurrence was confined to that age group. In late 1980s and 1990s, however, researchers demonstrated that it has been occurring, too, among adolescents and adults—with many of them undetected for several decades [1,3].
The prevalence of ADHD among children in the U.S. is approximately 9%, and this number holds true to other countries. More often than not, it is recognized among boys; however, it is also prevalent among girls, whose abnormal condition, most of the time, escaped medical detection. Among adults, approximately 4-5% of them worldwide have been suffering from the said medical problem but remained undetected and untreated. To date, there has been no known definitive cause of ADHD; however, research results show that in the causation [1].
So far, much still remains to be desired for the treatment of ADHD. Hence, Alcobra Ltd., an Israeli pharmaceutical firm, took the initiative to manufacture a drug intended to treat ADHD. This drug is named Metadoxine Extended Release (MDX), and it is considered as the lead and primary drug of Alcobra, specifically highlighting and emphasizing the claim that MDX is free of the abuse potential that other treatments for ADHD have [2]. Continue reading →